true
BD BBL™ Sensi-Disc™ antimicrobial susceptibility test discs
Achieve accurate, reliable, and convenient disc diffusion for antimicrobial susceptibility testing (AST) with our comprehensive portfolio of 110+ products.
- Overview
- Products & Accessories
- EIFU & Resources
- FAQ
Accurate and timely diagnosis can enable clinicians to make informed decisions, so they can help guide treatment for their patients. The BD BBL™ Sensi-Disc™ portfolio provides labs with an accurate, convenient, and broad range of disk diffusion solutions. One of the latest additions to our FDA-approved disk diffusion test portfolio is the Cefiderocol 30µg disc (28546).
Quality
BD’s stringent quality standards and experience in disc development and manufacturing results in discs that produce accurate and consistent results.
Comprehensive portfolio
To help address your emerging ID/AST needs, we continue to evolve our broad disk diffusion portfolio of +110 products.1 Our recent addition, the Cefiderocol 30µg disc can be used to determine susceptibility to Cefiderocol against bacteria for complicated urinary tract infections (cUTIs), hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.1
Aligned with standards
The drug content of our discs is assayed by the methods established by the FDA,1 and is the concentration recommended for AST by the Clinical and Laboratory Standards Institute (CLSI).2 Labs can confidently use them to standardize testing by the Kirby-Bauer disk diffusion method adopted as the consensus standard by CLSI.1 This procedure is also accepted by both the FDA3 and the WHO.4,5
Consistency
BD BBL™ Sensi-Disc™ test discs are 6-mm each and contain accurately determined amounts of antibiotic or other chemotherapeutic agents. Each disc is clearly marked on both sides with letters and numbers designating the agent and the drug content.1
Cost effective
BD BBL™ Sensi-Disc™ disc diffusion products offer an effective and more likely economical alternative for AST. Using our wide range of discs, you can enable versatile testing throughout your facility from one trusted source.
FDA: U.S. Food and Drug Administration; CLSI: Clinical Laboratory Standards Institute; WHO: World Health Organization
1. Cefiderocol IFU
2. Humphries, R. Differences in Disk Content Recommended by CLSI and EUCAST for Disk Diffusion Testing. 2019. CLSI and EUCAST recommendations for Disk Diffusion Testing
3. Clinical and Laboratory Standards Institute (formerly National Committee for Clinical Laboratory Standards). 2003. Approved standard M02 Ed 2018. Performance standards for antimicrobial disk susceptibility tests, 13th ed. NCCLS, Wayne, PA.
4. Federal Register. 1972. Rules and regulations. Antibiotic susceptibility discs. Fed. Regist. 37: 20525-20529. Erratum, 38: 2756, 1973.
5. Ericsson, H.M., and J.C. Sherris. 1971. Antibiotic sensitivity testing. Report of an international collaborative study. Acta Pathol Microbiol Scand. Sec. B. Suppl. 217: 1-90.
6. World Health Organization Expert Committee on Biological Standardization. 1977. Technical report series 610. W.H.O., Geneva.
1. Ahman J, et al., The quality of antimicrobial discs from nine manufacturers- EUCAST evaluations in 2014 and 2017, Clinical Microbiology and Infection(2018), https://doi.org/10.1016/j.cmi.2018.05.021.
true
Literature
BD's collection of literature on industry and on our offerings gives you information you can use to continue striving for excellence.
Learn more
true
1. Ahman J, et al., The quality of antimicrobial discs from nine manufacturers- EUCAST evaluations in 2014 and 2017, Clinical Microbiology and Infection(2018), https://doi.org/10.1016/j.cmi.2018.05.021.
true
false
true